Endo International PLC (NASDAQ:ENDP) (TSE:ENL)‘s stock had its “buy” rating restated by Mizuho in a research note issued on Tuesday, September 12th. They currently have a $14.00 price objective on the stock, down from their prior price objective of $19.00. Mizuho’s target price would indicate a potential upside of 61.66% from the stock’s current price.
Other equities analysts also recently issued reports about the company. Deutsche Bank AG decreased their price target on Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, July 7th. Morgan Stanley cut their target price on shares of Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating on the stock in a report on Thursday, August 10th. Royal Bank Of Canada set a $15.00 target price on shares of Endo International PLC and gave the stock a “hold” rating in a report on Monday, June 12th. Stifel Nicolaus cut shares of Endo International PLC from a “buy” rating to a “hold” rating and cut their target price for the stock from $22.00 to $15.00 in a report on Friday, June 9th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a report on Thursday, June 8th. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $14.33.
Endo International PLC (NASDAQ:ENDP) opened at 8.66 on Tuesday. The company’s market cap is $1.93 billion. Endo International PLC has a 12 month low of $7.41 and a 12 month high of $23.98. The firm has a 50-day moving average price of $8.73 and a 200 day moving average price of $10.80.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.74 by $0.19. The company had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The firm’s revenue was down 4.9% compared to the same quarter last year. During the same period last year, the company posted $0.86 earnings per share. Equities research analysts predict that Endo International PLC will post $3.52 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first reported by BBNS and is owned by of BBNS. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/endo-international-plc-endp-rating-reiterated-by-mizuho/1639595.html.
In other news, CFO Blaise Coleman bought 6,500 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was purchased at an average price of $7.89 per share, with a total value of $51,285.00. Following the transaction, the chief financial officer now directly owns 13,729 shares in the company, valued at $108,321.81. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Terrance J. Coughlin acquired 20,000 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were bought at an average cost of $7.70 per share, with a total value of $154,000.00. Following the transaction, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 36,000 shares of company stock valued at $279,460. 0.50% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in ENDP. James Investment Research Inc. bought a new stake in Endo International PLC in the second quarter valued at about $113,000. Blair William & Co. IL bought a new stake in Endo International PLC in the second quarter valued at about $126,000. Point View Wealth Management Inc. increased its stake in Endo International PLC by 16.6% in the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after acquiring an additional 1,900 shares during the period. Riverhead Capital Management LLC increased its stake in Endo International PLC by 64.4% in the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after acquiring an additional 5,887 shares during the period. Finally, Bank of Hawaii bought a new stake in Endo International PLC in the second quarter valued at about $180,000. 90.71% of the stock is owned by institutional investors and hedge funds.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with our FREE daily email newsletter.